ARVN opened at $6.37 on Monday. The firm has a market cap of $438.08 million, a PE ratio of -2.30 and a beta of 2.30. The stock has a 50-day moving average price of $13.91 and a 200-day moving ...

So should Arvinas (NASDAQ:ARVN) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $32.00. The company’s shares ...

Arvinas, Inc. (ARVN) has been on a downward spiral lately with significant selling pressure. After declining 25.4% over the past four weeks, the stock looks well positioned for a trend reversal as ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports.

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $24.00. The company’s shares ...

Arvinas, Inc. announced promising preclinical results for ARV-393, a targeted protein degrader aimed at treating non-Hodgkin lymphoma, particularly high grade B-cell lymphomas. Data showed that ...

Price Action: ARVN stock is down 4.93% at $6.56 at the last check on Friday.

Arvinas, Inc. (NASDAQ:ARVN) develops treatments that break down disease-causing proteins using its PROTAC (Proteolysis Targeting Chimera) technology. The company’s main drugs target prostate ...